The American journal of psychiatry
December 1, 2024
Lauren M. Sippel, Jessica L. Hamblen, Benjamin Kelmendi et al.
11 citations
PTSD is common and can become chronic without treatment. First-line treatments are individual trauma-focused psychotherapies, with antidepressants and non-trauma-focused psychotherapies also evidence-based. Many patients do not fully recover, prompting a search for novel treatments. This review critically evaluates emerging pharmacological and somatic interventions, including medication-assisted psychotherapy (e.g., MDMA), novel monotherapies (e.g., ketamine, cannabidiol), and neuromodulation (e.g., transcranial magnetic stimulation), as well as treatments of increasing interest (hyperbaric oxygen, stellate ganglion block, neurofeedback). Evidence for most novel treatments is preliminary and highly variable, though data for transcranial magnetic stimulation are encouraging.
Am J Psychiatry
January 1, 2025
Aaron S. Wolfgang, Vetisha L. McClair, Paula P. Schnurr et al.
6 citations
The Veterans Health Administration (VHA) is exploring the integration of psychedelic-assisted therapy as a potential treatment for veterans with mental health conditions, particularly PTSD. The text outlines the need for careful research and implementation strategies within the VHA system, emphasizing safe integration, care pathways, and the development of clinical protocols. It highlights the importance of addressing regulatory, ethical, and logistical challenges to ensure veteran well-being and recovery. The work suggests that psychedelic-assisted therapies could offer innovative treatment options, but rigorous study and structured implementation are necessary before widespread adoption.
Journal of Traumatic Stress
March 12, 2026
Leslie A. Morland, B O Rothbaum, Lauren M. Sippel et al.
2 citations
MDMA-assisted psychotherapy for PTSD shows promising results in recent randomized controlled trials, with high response and remission rates, but the FDA declined to approve it in August 2024 due to insufficient evidence. This review examines the current scientific literature on MDMA-AT, covering proposed mechanisms, methodological strengths and limitations, evidence gaps, and clinical, ethical, and regulatory issues. Key limitations include challenges with blinding, lack of active comparator conditions, no head-to-head comparisons of different therapy models, inadequate safety monitoring, and limited sample generalizability. Emerging research integrates MDMA with established trauma-focused therapies like prolonged exposure and cognitive processing therapy to leverage MDMA's effects on cognitive behavioral mechanisms.